Posted by Michael Wonder on 11 Feb 2021
FDA approves first in class Evkeeza (evinacumab-dgnb) for patients with ultra rare inherited form of high cholesterol
11 February 2021 - In pivotal Phase 3 HoFH trial, adding Evkeeza to standard lipid-lowering therapies reduced ow-density lipoprotein cholesterol by nearly half at 24 weeks, compared to placebo.
Regeneron Pharmaceuticals today announced that the U.S. FDA approved Evkeeza (evinacumab-dgnb) as an adjunct to other low-density lipoprotein cholesterol lowering therapies to treat adult and paediatric patients aged 12 years and older with homozygous familial hypercholesterolaemia.
